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Summary
 
We have developed a unique in vivo system to determine the relationship between endoge-
nous altered peptide ligands and the development of major histocompatibility complex class II–
restricted T cells. Our studies use the 3.L2 T cell receptor (TCR) transgenic mouse, in which
T cells are specific for Hb(64–76)/I-E
 
k
 
 and positively selected on I-E
 
k
 
 plus self-peptides. To this
endogenous peptide repertoire, we have individually added one of six well-characterized 3.L2
ligands. This transgenic approach expands rather than constrains the repertoire of self-peptides.
We find that a broad range of ligands produce negative selection of thymocytes in vivo. When
compared with the in vitro TCR–ligand binding kinetics, we find that these negatively select-
ing ligands all have a half-life of 2 s or greater. Additionally, one of two ligands examined with no
detectable binding to the 3.L2 TCR and no activity on mature 3.L2 T cells (Q72) enhances the
positive selection of transgenic thymocytes in vivo. Together, these data establish a kinetic thresh-
old between negative and positive selection based on the longevity of TCR–ligand complexes.
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T
 
cell development in the thymus depends upon the in-
teraction between the 
 
a
 
/
 
b
 
 TCR and self-peptides
bound to MHC molecules expressed on thymic APCs and
on thymic stromal cells (1–6). This recognition is flexible,
in that any given TCR has the capacity to interact at some
level with a broad spectrum of related MHC/peptide
ligands (7). For mature T cells, the functional correlates of
these interactions are well described and include full activa-
tion, partial activation, and antagonism (8–11). For devel-
oping thymocytes, productive engagement of the TCR re-
sults either in continued maturation (positive selection) or
in activation-induced cell death (negative selection). This
apparent paradox, where TCR recognition of a single set
of MHC ligands results in two very different functional out-
comes, has led to the proposal that the fate of each develop-
ing T cell depends on the strength and timing of TCR–MHC
interaction (12–15). In this hypothesis, “weak” interactions
promote positive selection, while “strong” interactions lead
to thymocyte activation and cell death. No specific interac-
tion with ligand results in death by neglect (16).
T cell signaling is a complex series of events which begins
with localization of the TCR to areas of contact between T
cell and APC. This localization or clustering results in sig-
nal transduction, which begins by phosphorylation of the
CD3 
 
z
 
 chain (17). These events have been studied exten-
sively in mature T cells, where evidence suggests that the
potency of each ligand is determined by the half-life of the
TCR–MHC complex (18–22). In this kinetic model of
T cell activation, weak interactions are those with a short
half-life. The short half-life limits formation of the contact
cap, reduces T cell clustering, and produces a pattern of
 
z
 
 phosphorylation distinct from that seen with more potent
ligands. Conversely, a long half-life of the TCR–MHC
complex allows for complete 
 
z
 
 chain phosphorylation,
Zap-70 recruitment to the signaling complex, a rise in in-
tracellular calcium, and T cell activation as measured by
IL-2 production (23, 24).
When thymocyte development is used to measure ligand
strength, the data is open to interpretation. Although many
studies are at least consistent with a kinetic model of T cell
selection (14, 25–28), some have suggested that integration
of TCR signaling is based on TCR occupancy (12, 29–32).
In an occupancy model, weak ligands have low equilibrium
binding affinities (30). Ligands with low equilibrium bind-
ing affinity but at high concentration could occupy suffi-
cient TCR for T cell signaling, resulting in positive selec-
tion (32). High-affinity ligands at low concentration could
have the same effect (29). Thus, for each developing thy- 
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mocyte there is predicted to be an occupancy threshold be-
tween positive and negative selection, which is determined
by the product of ligand concentration and ligand equilib-
rium binding affinity (30, 33). One problem with this view is
that T cells selected on low concentrations of a high-affinity
ligand are not functional (27). Also, ligands with low equi-
librium binding affinities often have fast off-rates, thereby
blurring the distinction between kinetic and occupancy
models (32). A clear understanding of how kinetic factors
influence thymic selection and which factors are important
has not been achieved.
These observations and others (34–40) support the con-
clusion that positive selection of both class I– and class II–
restricted T cells is peptide specific. They suggest that certain
kinetic parameters of the interaction between a TCR and
its peptide/MHC ligand regulate the activation of mature
T cells and determine the fate of developing thymocytes.
For MHC class I–restricted T cells, this analysis has been
facilitated through the use of fetal thymic organ culture
(FTOC) by allowing investigators to examine a large num-
ber of ligands (12, 14, 25, 28). For class II–restricted T cells,
the precise contribution of peptides to thymic selection has
been difficult to dissect (41, 42). No comparable FTOC sys-
tem exists for studying selection of MHC class II–restricted
T cells. Instead, investigators have focused on experiments
using a single peptide ligand attached to an MHC mole-
cule, expressed at high concentration (32, 43–46). How ei-
ther of these systems relates to in vivo biology has not been
firmly established, and any strict correlation between the
biological activity (binding kinetics) of the selecting ligand
and the ligand’s effect on T cell development remains to be
determined.
In this report, we present results obtained with a novel
system designed to determine how self-peptides influence
the selection of class II–restricted T cells in vivo. We describe
the functional consequences for a single antigen-specific T cell
when an extended spectrum of well-characterized altered
peptide ligands (APLs)
 
1
 
 of hemoglobin peptide Hb(64–76)
are individually expressed in the thymi of TCR transgenic
mice at physiologic levels. Thus, our approach differs sig-
nificantly from other studies of class II–restricted T cells in
that we have expanded rather than constrained the reper-
toire of self-peptides. Results demonstrate that a surpris-
ingly broad range of ligands produce negative selection of
transgenic T cells. Importantly, we have identified a single
ligand, one with no effect on mature T cells, that enhances
positive selection of thymocytes with the transgenic recep-
tor. When viewed in the context of the equilibrium bind-
ing kinetics (47) and the activity of these ligands on mature
 
T cells (48), these data define a kinetic threshold for nega-
tive selection of 3.L2tg T cells where the outcome is deter-
mined by the half-life of the TCR–ligand complex. They
suggest that positive selection of MHC class II–restricted
T cells involves specific interactions with ligands which
have short half-lives. Taken together, our studies are most
consistent with a kinetic model of thymic selection.
 
Materials and Methods
 
Transgenic Mice.
 
Lines of transgenic mice were generated that
express a membrane form of hen egg-white lysozyme (mHEL)
containing Hb(64–76) or one of five different APLs of Hb(64–
76) as an epitope tag. The self-peptide Hb(64–76) is derived from
the minor d allele of the 
 
b
 
 chain of mouse Hb. When presented
by I-E
 
k
 
, this epitope is recognized by the 3.L2 T cell hybridoma
and clone (49). Many of the APLs recognized by 3.L2 T cells in-
volve substitutions at the 72 position of the Hb(64–76) peptide,
the TCR contact residue in the middle of the MHC/peptide
complex (P5 position) as determined by crystallography (50). The
specific ligands and APLs studied in this report are Hb(64–76),
Hb(64–76) N72T, Hb(64–76) N72I, Hb(64–76) N72A, Hb(64–
76) N72Q, and Hb(64–76) N72E. Henceforth these ligands are
called N72(wt), T72, I72, A72, Q72, and E72.
The epitope tags were placed between amino acids 43 and 44
of mHEL, and the transgenic mice were generated as described
previously (51). Expression of each transgenic construct was con-
trolled by the MHC E
 
a
 
 promoter, limiting expression to all class
II–positive cells (43, 52). Founders were obtained, characterized,
and bred to the 3.L2tg mouse, which is specific for Hb(64–76)/I-E
 
k
 
(53), and the 3A9 TCR transgenic mouse, which is specific for
HEL(46–61)/I-A
 
k
 
 (54). Progeny were screened by PCR analysis
of purified tail digest DNA, and all mice used in experiments
were heterozygotes for TCR and mHEL/APL transgenes.
 
Peptides.
 
The peptides used in this study were synthesized, pu-
rified, and analyzed as described previously (48). The peptide se-
quences, in single letter amino acid code, are: GKKVITAFNEGLK
[N72(wt)]; GKKVITAFQEGLK (Q72); and NTDGSTDYGIL-
QINSR [HEL(46–61)].
 
T Cell Hybridoma Assays.
 
T cell hybridomas were used to de-
tect the presence of stimulatory ligands on splenocytes from
transgenic mice as described (51). In brief, increasing numbers of
splenocytes were incubated with 10
 
5
 
 hybridoma cells for 24 h.
Stimulation of each hybridoma was then determined by measur-
ing the level of IL-2 produced using the IL-2–dependent cell line
CTLL-2 as described (55). The hybridomas used in these assays
were 3.L2.12 (56), 3A9 (57), QC6.2, and QC85.5. The latter
two hybridomas were generated by immunizing CE/J mice with
the Q72 peptide, and each hybridoma was subcloned twice be-
fore use in this study. The QC6.2 hybridoma is specific for Q72,
whereas the QC85.5 hybridoma is stimulated by Q72, A72, T72,
and N72(wt).
 
Primary T Cell Proliferation.
 
Primary T cells were stimulated
with Hb(64–76) peptide as described (58). In brief, 5 
 
3
 
 10
 
5
 
 sple-
nocytes/well were incubated with increasing amounts of peptide
for 48 h, pulsed with 0.4 
 
m
 
Ci of [
 
3
 
H]TdR for 18 h, and har-
vested. Proliferation was measured as cpm incorporated (mean of
triplicate wells). Results from several experiments were then
averaged to obtain the data shown in Fig. 4.
 
Antibodies.
 
The antibodies used were PE-conjugated anti–
mouse CD4 (PharMingen); FITC-conjugated anti–mouse CD8a
(PharMingen); biotinylated 3.L2 clonotypic antibody (53); bio-
 
1
 
Abbreviations used in this paper:
 
 APL, altered peptide ligand; APLtg, trans-
genic mouse expressing mHEL/APL in all class II–positive cells; CAB,
3.L2 clonotypic antibody; DN, double-negative (CD4
 
2
 
CD8
 
2
 
); DP, dou-
ble-positive (CD4
 
1
 
CD8
 
1
 
); Hb, hemoglobin; HEL, hen egg-white
lysozyme; 3.L2tg, 3.L2 TCR transgenic mouse; mHEL/APL, chimeric
membrane protein containing HEL and one of the APLs listed below;
N72(wt), the native Hb(64–76) peptide with asparagine at position 72;
RT, room temperature; SP, single positive; T72, I72, A72, Q72, and
E72, APLs of Hb(64–76) with position 72 substitutions as indicated. 
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tinylated 3A9 clonotypic antibody (51); biotinylated F10.6.6 (59);
and biotinylated 14-4-4S (60). Cells stained with biotinylated an-
tibodies were subsequently incubated with Tricolor-streptavidin
(Caltag) or PE-streptavidin (Caltag).
 
Flow Cytometry.
 
Single-cell suspensions of thymocytes or
splenocytes were stained in FACS buffer (PBS supplemented
with 0.5% BSA and 0.1% sodium azide) using the following pro-
tocol. Aliquots of cells (10
 
6
 
/sample in 100 
 
m
 
l FACS buffer) were
placed in polypropylene culture tubes (12 
 
3
 
 75 mm; VWR) and
incubated on ice for 1 h with the biotinylated or directly labeled
antibodies. Cells were then washed once with 3 ml of FACS
buffer and incubated for 30 min on ice with the streptavidin-fluo-
rochrome conjugate where appropriate. Cells were washed again,
fixed for 18–24 h in FACS buffer plus 1% paraformaldehyde, and
analyzed on a FACScan
 
®
 
 (Becton Dickinson) flow cytofluorome-
ter using CELLQuest
 
®
 
 (Becton Dickinson) software. Samples
were gated on live cells, and 10
 
5
 
 live cell events per sample were
collected.
 
Single-label Immunocytochemistry.
 
Thymi from 8–16-wk-old
transgenic mice and nontransgenic littermates were excised, em-
bedded in OCT compound (Tissue-Tek), and frozen in liquid ni-
trogen. Thymic tissue was then cut into sagittal sections (4 
 
m
 
m
thick), mounted on glass slides, and fixed in acetone for 10 min at
room temperature (RT). Sections were stored at 
 
2
 
70
 
8
 
C. Before
immunolabeling, fixed tissue sections were allowed to reach RT
and were washed three times in PBS. To block binding of anti-
body reagents to endogenous Fc receptors, either supernatant from
the 2.4G2 hybridoma was applied (neat) for 15 min at RT or puri-
fied anti–mouse CD16/CD32 (PharMingen) diluted 1:200 (2.5
 
m
 
g/ml) in PBS blocking buffer (PBS, pH 7.4, with 0.1% BSA, 5%
normal mouse serum) was applied for 15 min at RT. Tissues were
then washed three times in PBS. To block nonspecific binding of
secondary streptavidin reagents to endogenous biotin, sections
were incubated in avidin D and biotin blocking solutions (Vector
Labs), respectively, for 15 min. Tissues were washed three times in
PBS before and after each blocking application.
Biotin-conjugated primary antibodies were diluted in PBS
blocking buffer and applied to tissues for overnight incubation in
a humidified chamber at 4
 
8
 
C. To detect mHEL/APL transgene
expression, biotinylated F10.6.6 was diluted 1:25 (33 
 
m
 
g/ml) and
applied as above. For detection of MHC class II expression, bio-
tinylated 14-4-4S was diluted 1:50 (10 
 
m
 
g/ml) and applied as
above. Tissues were then washed three times in PBS. Cy3-conju-
gated streptavidin (Jackson ImmunoResearch Laboratories) was
diluted in PBS blocking buffer 1:1,000 (1 
 
m
 
g/ml) and applied for
30 min at RT. After tissues were washed three times in PBS,
coverslips were mounted to slides in PBS/glycerol (1:1). To con-
trol for irrelevant binding of F10.6.6, thymi from nontransgenic
littermates were stained according to the above protocol. To
control for nonspecific binding of Cy3-conjugated streptavidin,
anti-TNP IgG
 
1
 
 (PharMingen) and anti-TNP IgG
 
2
 
 (PharMingen)
were diluted 1:25 in PBS blocking buffer and applied as primary
antibodies. Immunofluorescence was visualized on a Zeiss Axio-
phot microscope. Electronic images were captured by a Spot
camera (Diagnostic Images, Inc.) and processed using Northern
Eclipse version 2.0 software.
 
Results
 
APCs Express the Chimeric mHEL/APL Transgenes at Equiv-
alent Levels.
 
These experiments are designed to study the
functional consequences for T cells when endogenous APLs
were expressed in the thymus and in the periphery. The
system is based on the self-antigen Hb, and uses the 3.L2
TCR transgenic mouse (3.L2tg), which is specific for
Hb(64–76)/I-E
 
k
 
 (53). The 3.L2tg mouse is ideally suited
for these studies, as positive selection of the transgenic re-
ceptor is moderate in H2
 
k
 
 mice, making it possible to ob-
serve enhanced positive as well as negative selection. To
the 3.L2tg mouse, we have genetically introduced APLs of
Hb(64–76). These APLs differ by as much as 150,000-fold
in their relative activity towards mature 3.L2 T cells (48),
and the relative activity correlates with the half-life of the
TCR–ligand complex (47; Table I). Ligand levels in the
APLtg mice are clearly physiologic, and peptide presenta-
tion is achieved through normal antigen processing path-
ways. Thus our approach should be distinguished from
experiments using mice which express a single peptide co-
valently attached to the class II 
 
b
 
 chain (32, 43). In this lat-
ter approach, ligand levels are much higher than those
achieved under normal circumstances, and the covalent
linker may potentially influence binding of the peptide to
the class II molecule.
Our strategy for introducing these ligands into the 3.L2
TCR transgenic mouse was recently published for mice
expressing the antagonist A72 (51). In brief, the APLs are
introduced as an epitope tag contained within a carrier pro-
tein in transgenic mice. This carrier protein is a membrane
form of HEL whose expression is controlled by an MHC
E
 
a
 
 promoter. The E
 
a
 
 promoter was derived from the es-
tablished expression vector pDOI-5, which has been shown
to efficiently target expression of transgenes to all class II–
positive cells in the thymus and the spleen (43, 52). As in-
tegral membrane proteins, all transgenes are also targeted to
the class II antigen processing and presentation pathway
(61, 62). The APLtg mice are then bred to the 3.L2tg mice,
and the progeny are analyzed. Thus, the net effect of this
approach is to add one specific ligand for 3.L2 T cells to the
pool of endogenous ligands already present in the B6.AKR
background. The specific Hb(64–76)–related ligands de-
 
Table I.
 
A Comparison of 3.L2 Ligands
 
Ligand
Relative
activity
 
*
 
Half-life
 
‡
 
K
 
D
 
 equilibrium
 
§
 
K
 
D
 
 
 
k
 
off
 
/
 
k
 
on
 
s
 
m
 
M
 
m
 
M
 
N72(wt) 100 10.8 52 12.0
T72 2 5.1 54 9.9
I72 0.006 2.3–3.4 62.5 10–20
A72 0.0007
 
,
 
2 170 —
Q72 none — — —
E72 none — — —
Data are from reference 47.
 
*
 
Relative activities were determined by a B cell apoptosis assay.
 
‡
 
Half-life refers to the longevity of the 3.L2 TCR–APL complex as
measured by BIAcore™ experiments.
 
§
 
K
 
D
 
 values determined by Scatchard equilibrium analysis. 
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scribed in this report are N72(wt), the natural epitope with
an Asn at position 72; T72, a weak agonist; I72, an antago-
nist; Q72, a “null” ligand with no effect on mature T cells;
and E72, also a null ligand. Note that we also include new
data from the A72tg mouse, as it is instructive to consider
these data in the context of the spectrum of APLs described
in this report.
Thymic expression of the mHEL/APL proteins and I-E
 
k
 
from each transgenic line was assessed by immunofluores-
cence of frozen sections using mAbs. Results shown in Fig. 1,
A–F, demonstrate that each line expresses the mHEL/APL
protein in both the thymic cortex and medulla. Further-
more, the pattern of expression observed is identical to that
seen for MHC class II (Fig. 1, G and H). Peripheral expres-
sion of the transgenes was determined by two-color
FACS
 
®
 
 analysis of splenocytes. The results shown in Fig. 2
demonstrate that each line expresses the mHEL/APL pro-
tein in all MHC class II–positive
 
 
 
cells. This population rep-
resents 
 
z
 
60% of splenocytes and is largely B220
 
1
 
 
 
(not
shown). Importantly, none of the transgenes appears to in-
fluence MHC class II expression in the thymus or in the
periphery, as the data demonstrate that class II expression in
these six transgenic lines is identical (Fig. 2, and data not
shown). Within a given line, identical levels of mHEL/
APL expression are seen in splenocytes from 3–4-wk-old
mice and in the 6–12-wk-old mice used in this study (data
not shown). This implies that any potential differences in
the timing of embryonic transgene expression could not in-
fluence T cell development in mature mice. However,
when comparing one line to another, slight variability in
the level of transgene expression was noted. Using both bio-
tinylated and directly labeled bivalent F10.6.6, we estimate
Figure 1. All mHEL/APL
transgenes are expressed in both
the thymic cortex and thymic
medulla. Frozen thymic sections
were stained for either an HEL
epitope common to all transgenes
(A–F, I, and J) or I-Ek (G and H)
as described in Materials and
Methods. The original magnifica-
tion of all photographs is 203
unless otherwise specified. The
cortex (C) and medulla (M) of
each section are labeled. Note that
mHEL/APL expression in the
thymus did not influence MHC
class II expression (shown only for
the E72 and Q72 lines in G and
H, respectively). Also, the relative
intensity of fluorescence detected
with the anti-HEL antibody
matched that seen by FACS®
analysis of splenocytes using the
same primary reagent [N72(wt) .
T72  .  E72  .  I72  .  A72  .
Q72]. A–F, K, and L are from a
representative experiment in
which all photographs shown
were taken on the same camera
settings (14-s exposure, gain of 4;
original magnification: 203). G–J
were from another experiment: G
is the E72 thymus stained for I-Ek
(6-s exposure, gain of 4; original
magnification: 203); H is the
Q72 thymic cortex stained for
I-Ek (8-s exposure, gain of 2; orig-
inal magnification: 403); I is the
N72(wt) thymic cortex stained for
mHEL/APL expression (12-s ex-
posure, gain of 8; original magni-
fication: 403); J is the Q72 thy-
mic cortex stained for mHEL/
APL expression (14-s exposure,
gain of 4; original magnification:
403). The mHEL/APL-specific
antibody does not bind nontrans-
genic thymus (K), and there is no
nonspecific binding of the strepta-
vidin-Cy3 reagent (L). This entire
experiment was repeated four
times with similar results. 
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that at most there is a three- to fivefold difference in cell
surface expression of the various chimeric proteins, with
N72 the highest, Q72 the lowest, and ranked as follows:
N72(wt)
 
 . 
 
T72
 
 . 
 
E72
 
 . 
 
I72
 
 . 
 
A72
 
 . 
 
Q72 (Figs. 1 and 2,
and data not shown). These data demonstrate expression of
the mHEL/APL proteins at similar levels and in all MHC
class II–positive cells in both the thymus and the periphery.
Figure 2. The mHEL/APL transgenes are expressed in all MHC class II–
positive cells. Splenocytes from each transgenic line were stained for HEL
epitopes common to all transgenes and I-Ek using mAbs. Dot plots from two-
color FACS® analysis of stained cells from one of five similar experiments are
shown (log10 fluorescence). All experiments demonstrate expression of the
transgenes in MHC class II–positive splenocytes at comparable levels. Trans-
gene expression using the Ea promoter does not influence endogenous class
II expression.
 
Table II.
 
Summary of FACS
 
®
 
 Analysis Data from mHEL/APLtg 
 
3
 
 3.L2tg Mice
 
Mouse
Thymus Spleen
 
n
 
Age
%
CD4-SP
%
DP
%
DN
%
CD8-SP
CD4
 
1 
 
gate:
% CAB
 
hi
 
Size
%
CD4
 
1
 
%
CD8
 
1
 
CD4
 
1 gate:
% CABhi Size
wk 3 106 3 106
3.L2tg 36 8.5 10.2 70.7 13.9 3.8 58.6 6 1.5* 108 6 9* 9.4 4.4 50.0 6 2.4* 159 6 13*
N72tg 3
3.L2tg 8 10.4 6.2 62.4 24.8 6.7 0.4 6 0.1 69 6 6 5.0 4.4 2.7 6 1.7 224 6 15
T72tg 3
3.L2tg 8 10.5 7.9 44.1 41.9 6.1 4.2 6 0.6 42 6 12 4.6 2.1 6.7 6 1.8 130 6 19
I72tg 3
3.L2tg 10 8.4 6.9 57.2 27.4 8.5 1.8 6 0.6 49 6 6 5.5 3.8 3.0 6 0.8 176 6 32
A72tg 3
3.L2tg 8 12.0 10.3 74.5 11.8 3.4 37.5 6 5.3 123 6 12 11.8 6.2 37.0 6 4.2 148 6 24
Q72tg 3
3.L2tg 16 12.1 9.9 70.4 12.9 3.8 70.4 6 2.3 81 6 11 11.1 4.8 52.9 6 2.4 131 6 14
E72tg 3
3.L2tg 9 7.0 9.7 74.7 12.8 2.6 57.8 6 1.2 86 6 6 8.0 3.4 44.5 6 2.3 147 6 28
mHELtg 3
3.L2tg 9 11.4 9.7 71.1 16.4 2.8 59.3 6 3.5 60 6 6 8.6 4.8 45.3 6 4.0 218 6 16
*SEM.
The Effect of Most APLs on Developing Thymocytes Correlates
with their Effect on Mature T Cells. We tested the effect of
each endogenous APL on 3.L2 T cell development by cross-
ing 3.L2tg mice with APLtg mice, and then performing
three-color FACS® analysis on thymocytes. All mice exam-
ined were heterozygotes for the TCR and/or mHEL/APL
transgenes, approximately equally distributed between male
and female, and ranged from 6 to 12 wk of age. Where
possible, 3.L2tg-only littermates were used as positive con-
trols; otherwise, age-matched 3.L2tg heterozygotes were
selected. For each cross, we examined at least 8 mice, and
in the case of Q72tg 3 3.L2tg we examined 16 mice (Table
II). CD4 single-positive (SP) cells were analyzed for their
expression of the 3.L2 clonotypic receptor. For each exper-
iment, the location of the quadrants, the CD4-SP region,
and the marker delineating CD4-SP, 3.L2 clonotypehi anti-
body (CAB)hi population of cells was set using the 3.L2tg
control. These same markers or gates were used to analyze
the experimental population. The data are summarized in
Table II. Note that the 3.L2tg phenotype is based on analy-
sis of 36 thymi and 26 spleens.
For each cross, examples of CD4 versus CD8 dot plots
and histograms showing CAB expression in the CD4-SP
population are shown in Fig. 3. In the histograms, the 3.L2
control is shown as a dotted line, and the experimental
condition as a heavy solid black line. The ligands are listed
in order of their effect on mature T cells (48): N72(wt), the
strongest agonist; T72, a weaker agonist; I72, an antagonist;
A72, a weaker antagonist; Q72, a ligand with no effect on1536 APLs and T Cell Development
mature 3.L2 T cells; and E72, a ligand with no effect on ma-
ture T cells and with a negatively charged residue replacing
the normal asparagine.
As expected, we find that expressing the 3.L2 TCR ago-
nist N72(wt) in the thymus of 3.L2tg mice results in com-
plete negative selection of all thymocytes with the trans-
genic receptor (Fig. 3). Overall, the thymus size is about half
that seen in 3.L2 controls, there are fewer CD41CD81
double-positive (DP) and CD4-SP thymocytes, and increased
numbers of double-negative (DN) cells (Table II). There are
no CD4-SP cells with the clonotypic receptor. The weaker
agonist T72, a ligand that is 50-fold less active (48), has an
identical effect when expressed in the thymus of 3.L2tg
mice. Most surprisingly, thymic expression of the antago-
nist I72 also results in complete negative selection of spe-
cific T cells. The weaker antagonist A72 produces only
modest negative selection, as described previously (51). We
conclude that, for the 3.L2 TCR, the range of negatively
selecting ligands in vivo is broad, and includes ligands that
function as agonists and as antagonists of mature T cells.
The Ligand Q72 Has No Effect on Mature T Cells but En-
hances Positive Selection. Of significant interest, adding the
ligand Q72 to the pool of endogenous ligands already
present on the B6.AKR background results in an increase
in the percentage of CD4-SP cells with high levels of the
3.L2 TCR over that seen in 3.L2tg control mice (Table II).
This difference is 12% and is statistically significant, with P ,
0.01. Also note that the percentage of thymocytes in the
CD4-SP quadrants of these two groups is the same, and
that the overall size of thymi in the two groups is also ap-
proximately the same. Thus, this increase in the proportion
of CD4-SP, CABhi cells is likely to represent an increase in
Figure 3. The effects of APLs on the thy-
mic selection correlate with the relative ac-
tivity of these ligands on mature T cells. (A)
Three-color FACS® analysis of thymocytes
derived from APLtg 3 3.L2tg F1 mice was
performed, with 105 live cell events col-
lected per sample. The results were first ex-
amined as dot plots of CD4 (PE) versus
CD8 (FITC), and the CD4-SP region was
selected for further analysis. Representative
thymi are depicted (log10 fluorescence),
with the results from all mice summarized
in Table II. (B) The CD4-SP gates in A
were analyzed for expression of the 3.L2
clonotypic receptor (CAB-biotin plus Tri-
color-streptavidin). The results are shown as
histograms of cell number versus log10 fluo-
rescence for both APLtg 3 3.L2tg mice
(solid lines) and 3.L2tg littermate controls
(dotted lines). The ligands are listed in terms
of their relative activity on mature T cells
from strongest (top) to weakest (bottom)
(reference 48). The interpretation, based on
the cumulative observed effects for each
APL, is listed beside the histogram.1537 Williams et al.
the absolute number of cells with the 3.L2 TCR. When
Q72 is replaced by E72, this effect is not observed and 3.L2 3
E72 mice are identical to 3.L2 mice, both in terms of
the number of CD4-SP thymocytes and the percentage of
CD4-SP thymocytes with high levels of the clonotypic re-
ceptor. It is important to note that the Q for N substitution
at position 72 conserves charge while lengthening the
amino acid side chain by one methyl group. This is in con-
trast to the E for N substitution, which both lengthens the
side chain and replaces the polar amide with a negatively
charged carboxyl group. Taken together, these data suggest
that ligands capable of positively selecting the 3.L2 TCR
are weak ligands like Q72, with no activity on mature T cells
but capable of forming specific interactions.
To further control for the effect of expressing a trans-
genic membrane protein in all APCs, we also crossed 3.L2tg
mice to a line of mice which express mHEL only, that is,
they lack the APL epitope tag but use the same Ea pro-
moter. We find that mice expressing the 3.L2 TCR and
mHEL are identical to 3.L2 mice (Table II). For example,
in these mice there are 9.7% CD4-SP thymocytes. Of these
CD4-SP cells, 59.3% are CABhi. This experiment provides
evidence that the effects we have observed are specific for
the epitope tags, and not a result of the HEL components
of the transgenes interfering with or altering processing and
presentation of endogenous epitopes.
The Peripheral Phenotype Is Generally Predicted by the Num-
ber of CD4-SP Thymocytes with High Levels of the Clonotypic
Receptor. Splenocytes from the mice analyzed above were
also examined by three-color FACS®. The data demonstrate
that when considering naive T cells, the peripheral pheno-
type is largely determined by selection events occurring in
the thymus. For example, the percentage of CD41 spleno-
cytes in N72tg 3 3.L2tg mice is roughly one half that seen
in 3.L2 controls (Table II). This decrease represents the loss
of all cells with high levels of 3.L2 TCR (Fig. 4, top left).
This same phenotype is also seen in T72tg 3 3.L2tg and
I72 3 3.L2tg mice. In A72tg 3 3.L2tg mice, a reduced
number of CD41CAB1 cells is seen. In the case of Q72tg 3
3.L2tg mice, a small increase in the percentage of CD41
CAB1 splenocytes is seen compared with 3.L2 controls. This
increase is not statistically significant. In E72tg 3 3.L2tg
mice, a slight reduction in the percentage of CD41CAB1
splenocytes is seen. Finally, there is no statistically signifi-
cant difference between mHEL-only 3 3.L2tg mice and
3.L2tg controls (Table II). Again, this implies that epitopes
from the mHEL portion of the constructs have not influ-
enced the results.
Interpretation of the data in negatively selecting mice is
relatively straightforward. Nearly all cells with the 3.L2
clonotypic receptor are eliminated in the thymus, and no
cells with high levels of this receptor are found in the
spleen. For the weaker ligands, interpretation of the data is
more complicated. There are many determinants, other
than genetic factors, that influence the size of the spleen
and the relative size of the CD41 and CD81 compart-
ments. In previous studies with the A72tg 3 3.L2tg mice,
we found that CD41CAB1 cells in the periphery were na-
ive. Yet antigen-induced expansion of any particular popu-
lation of splenocytes could clearly influence the relative
numbers of those cells. In this set of experiments, we did
not routinely examine the CD41CAB1 or the CD41
CAB2 populations of cells for activation markers, making
the potential contribution of such an event difficult to de-
termine. Also, we have not examined what influence, if
any, these ligands have on the survival of 3.L2tg T cells.
These caveats notwithstanding, the peripheral phenotypes
are generally consistent with those observed in the thymus,
in terms of the size of the CD41 compartment and the per-
centage of CD41CAB1 cells.
Figure 4. The number of CAB1 cells in the
periphery of APLtg 3 3.L2tg mice reflects the
effect of the APL on thymic selection. Three-
color FACS® analysis was performed on spleno-
cytes from APLtg 3 3.L2tg mice and 3.L2tg lit-
termate controls. Splenocytes were stained for
CD4 (PE), CD8 (FITC), and the 3.L2 clono-
typic receptor (CAB-biotin plus Tricolor-
streptavidin), and 105 live cell events were col-
lected per sample. Results were first examined
as dot plots of CD4 versus CD8 (not shown),
and the CD41 region was selected for further
analysis. The level of 3.L2 clonotypic TCR ex-
pression was determined in this population of
cells, and the results were plotted as histograms
of cell number versus log10 fluorescence. Rep-
resentative histograms are shown for each
APLtg  3 3.L2tg (solid lines) and for 3.L2tg lit-
termate controls (dotted lines).1538 APLs and T Cell Development
The Proliferative Response of Naive Splenocytes Reflects the
Selecting Background. We wished to determine the func-
tional state of naive T cells selected on the various APL
backgrounds. For these experiments, we added increasing
amounts of Hb(64–76) peptide to splenocytes as described
(51). Each curve represents the average cpm incorporated
at each antigen dose for all experiments performed. As
shown in Fig. 5 (top), splenocytes from the negatively
selecting backgrounds are tolerant. They proliferate only
weakly to high concentrations of Hb(64–76) peptide. For
N72 3 3.L2 mice, a response is first measurable at 1.0 mM,
compared with 0.003 mM for 3.L2 controls. Overall, these
data demonstrate a 500-fold shift in the dose–response
curve. T72tg 3 3.L2tg and I72tg 3 3.L2tg mice are also
tolerant, with 500- and 100-fold shifts in their response
curves, respectively.
The response of A72tg 3 3.L2tg splenocytes to Hb(64–76)
peptide was recently published (51). In that report, we
found that the presence of the endogenous antagonist A72
inhibited the proliferative response of 3.L2tg T cells. Using
an adoptive transfer approach, we have also observed pe-
ripheral antagonism with A72 in vivo (63). The reduced
response shown in Fig. 5 (bottom left) reflects both this pe-
ripheral antagonism and the reduced numbers of CD41
CAB1 cells present when all experiments are averaged. The
response of Q72tg 3 3.L2tg T cells is identical to 3.L2
controls at low and intermediate antigen doses. At doses
above 1.0 mM, the Q72tg 3 3.L2tg response is greater
than that seen in 3.L2tg controls, reflecting greater num-
bers of specific T cells proliferating. The response observed
in E72tg 3 3.L2tg mice is identical to 3.L2 controls, within
the error of the experiments.
We conclude from the above that 3.L2tg mice selected
on the endogenous ligands N72, T72, and I72 are tolerant
to Hb(64–76). A72 produces a degree of tolerance by pe-
ripheral antagonism as described (51). Expression of Q72 in
the thymus and spleen of 3.L2tg mice results in functional
T cells and a proliferative response slightly greater than
control mice. Finally, E72 has no effect on the response of
naive 3.L2 T cells to Hb(64–76) peptide.
APCs in the Spleen and Thymus Process and Present Both
Hb-related APL and HEL Epitopes from the Chimeric Proteins.
It was possible that differential processing and presentation
of the Hb-related APL epitopes in each founder line could
influence our interpretation by allowing us to either under-
estimate or overestimate the effect of any particular ligand.
Many of the ligands examined are not agonists for 3.L2tg
T cells, and there is no single assay available to detect pre-
sentation of these APL epitopes. Instead, we have used a
combination of T cell hybridomas and TCR transgenic
mice to provide convincing evidence that all chimeric pro-
teins are equivalently processed and presented in both the
thymus and the spleen of APLtg mice.
Processing and presentation of the relevant epitopes in
each chimeric protein were demonstrated by hybridoma
stimulation assays using splenocytes as APCs. The 3.L2.12
hybridoma is specific for Hb(64–76), and is weakly stimu-
lated (50-fold reduction) by T72 (48). As expected, as few
as 3 3 103 N72tg splenocytes stimulate the 3.L2.12 hybri-
doma (Fig. 6, top left). At higher numbers of splenocytes
Figure 5. The proliferative re-
sponses of naive splenocytes from
APLtg 3 3.L2tg mice are consis-
tent with the observed effects of
these ligands on T cell develop-
ment. They also demonstrate that
T cells selected on the Q72 back-
ground are functional. The prolif-
erative responses were measured
by tritiated thymidine incorpora-
tion. Splenocytes (5 3 105/well)
were added along with the indi-
cated concentrations of Hb(64–
76) peptide. Cells were incubated
for 48 h, pulsed with tritiated thy-
midine for 18 h, harvested, and
counted. Within a given experi-
ment, triplicate wells were per-
formed at each peptide concen-
tration, and the mean cpm was
determined. Each experiment was
repeated several times. Symbols
are as follows: d, N72tg (n 5 5);
j, T72tg (n 5 9); m, I72tg (n 5
11); e, A72tg (n 5 8); ,, Q72tg
(n 5 16); r, 3.L2tg (n 5 20); and
h, B6.AKR (n 5 5). The data
shown represent the average of
these experiments, with the error
calculated as SEM. The 3.L2tg
and B6.AKR controls are shown
in each panel for comparison.1539 Williams et al.
per well (105–106), T72tg splenocytes will also stimulate
the 3.L2.12 hybridoma, although this stimulation is re-
duced 35–50-fold compared with that achieved with
N72tg splenocytes and is not visible in the scale of the
graph. In a similar fashion, the hybridoma QC85.5 is stim-
ulated most strongly by the Q72 peptide, but will also pro-
duce IL-2 when stimulated by N72, T72, and A72. When
splenocytes from each transgenic mouse line were used as
APCs, the response observed was consistent with this ob-
servation, confirming the presence of these ligands (Fig. 6,
bottom right). Again, the response to N72tg and A72tg
splenocytes, while fivefold above background, is not visible
in the scale of the Q72tg response. The presence of the
Q72 ligand was also demonstrated by using Q72tg spleno-
cytes to stimulate the QC6.2 hybridoma (Fig. 6, bottom
left), which is specific for Q72 and no other APL of Hb
(64–76). Finally, APCs from all transgenic lines, regardless
of which specific APL of Hb(64–76) they express, should
also process and present epitopes from the common HEL
portion of the chimeric protein. This expectation was tested
with the 3A9 T cell hybridoma, which is specific for
HEL(46–61)/I-Ak. We find that splenocytes from all trans-
genic lines stimulate the 3A9 hybridoma, and that the in-
duced responses are equivalent (Fig. 6, top right).
Thymic expression, processing, and presentation of mHEL/
APL transgenic proteins were demonstrated by breeding
each line of APLtg mice to 3A9 TCR transgenic mice. T cells
in 3A9 TCR transgenic mice are specific for HEL(46–61)/
I-Ak, and therefore should be negatively selected in the
presence of this strong agonist ligand. As shown in Table
III and Fig. 7, this is indeed the case. When thymocytes
from mHEL/APL1/2, 3A91/2 mice were examined by
FACS® analysis for CD4, CD8, and the 3A9 clonotypic re-
ceptor, there were virtually no DP cells. The number of
CD4-SP (CD41CD82) cells was reduced by z75%, and in
this latter population no cells expressed the 3A9 clonotypic
TCR (shown for 3A9 3 Q72tg; Fig. 7 A, right). Consis-
tent with this observation, the size of thymi in 3A9 3
mHEL/APL mice was reduced by z80% relative to 3A9
littermate controls. In these mice, no splenocytes were
found with the 3A9 clonotypic receptor, and naive spleno-
cytes failed to proliferate to the HEL(46–61) peptide (not
shown). We conclude 3A9 3 mHEL/APL mice are toler-
ant to HEL(46–61), and the mechanism for this tolerance is
negative selection, demonstrating the presence of properly
processed and presented HEL(46–61) epitopes in the thymi
of all mHEL/APL mice.
In summary, these data clearly show that the APL por-
tion of each chimeric transgenic protein is processed and
presented by APCs in vivo. For those hybridomas stimu-
Figure 6. Both Hb-related APL and
HEL(46–61) epitopes from the chimeric
proteins are processed and presented. Sple-
nocytes from each transgenic line were used
as APCs in hybridoma proliferation assays to
demonstrate properly processed and pre-
sented APL and HEL epitopes. In brief, in-
creasing numbers of splenocytes per well
(3 3 102 to 1 3 106) were added to a fixed
number of T cell hybridoma cells per well
(105). The cells were incubated for 24 h, af-
ter which 100 ml of supernatant was re-
moved and assayed for IL-2 content by
CTLL-2 assay. Results are plotted as the
cpm incorporated in the CTLL-2 assay ver-
sus the number of splenocytes per well in
the original culture. Each datapoint is the
mean of triplicate wells. Considering the
spectrum of APLs used in this report,
3.L2.12 hybridoma is specific for Hb(64–
76)/I-Ek and stimulated weakly by T72;
QC6.2 is specific for Q72/I-Ek; QC85.5 is
specific for Q72/I-Ek and stimulated weakly
by T72, N72(wt), and A72; and 3.A9 is spe-
cific for HEL(46–61)/I-Ak. Most weak re-
sponses are not visible in the context of the
scale used for the predominant response.
This experiment was performed five times
with similar results, all of which clearly
demonstrate processing and presentation of
APL and HEL epitopes from the transgenic
proteins. Symbols are as follows: d, N72tg;
j, T72tg; m, I72tg; e, A72tg; ,, Q72tg;
s, E72tg; and h, the B6.AKR control.1540 APLs and T Cell Development
lated by more than one APL, the relative magnitude of the
response observed with splenocytes as APCs compares fa-
vorably with the response observed with purified peptide
in a standard hybridoma proliferation assay (48, and data
not shown). When considered together, these data strongly
suggest that each transgenic line expresses similar numbers
of I-Ek/APL complexes on APCs in both the thymus and
the periphery.
Table III. Summary of FACS® Analysis Data from mHEL/APLtg 3 3A9 Mice
Mouse
Thymus
n Age % CD4-SP % DP % DN % CD8-SP
CD41 gate:
% clonotypehi Size
wk 3 106
3A9 7 7.9 35.8 46.7 13.1 4.3 81.3 6 3.2* 155 6 29*
N72tg 3 3A9 3 8.0 10.8 2.2 82.4 4.6 ,2.0‡ 17 6 1
T72tg 3 3A9 3 5.0 2.8 0.5 94.3 2.2 ,2.0‡ 30 6 2
I72tg 3 3A9 2 9.0 16.2 1.8 80.2 1.8 ,2.0‡ 18 6 1
A72tg 3 3A9 3 11.0 10.3 0.9 81.1 2.7 ,2.0‡ 21 6 1
Q72tg 3 3A9 3 5.5 4.5 0.8 92.5 2.2 ,2.0‡ 18 6 5
E72tg 3 3A9 2 7.0 8.7 1.4 88.0 2.0 ,2.0‡ 10 6 1
*SEM.
‡Due to the small number of CD4-SP thymocytes in some experiments, the number of CD4-SP, clonotypehi cells was divided by the number of
CD4-SP, clonotypehi cells in the 3A9 control to obtain these percentages.
Figure 7. Expression of the mHEL/APL
transgenic proteins in the thymus results in
complete negative selection of 3A9 transgenic
T cells. (A) Three-color FACS® analysis was
performed on the mice described in Table III.
The left panel shows a dot plot of CD4 (PE)
versus CD8 (FITC) for a representative control
3A9 TCR transgenic mouse (log10 fluores-
cence). From this plot, the CD4-SP region was
selected for further analysis of 3A9 clonotypic
TCR expression. Shown in the right panel are
representative histograms derived from the
CD4-SP region of the 3A9 control and the
Q72tg 3 3A9 mouse shown in B. The histo-
gram plots the log10 fluorescence (biotinylated
3A9 clonotypic antibody plus Tricolor-strepta-
vidin) and the number of cells with the 3A9
TCR in these populations. The results clearly
demonstrate the complete loss of all CD4-SP,
3A9 TCRhi thymocytes in Q72tg 3 3A9 mice.
Identical results were obtained with all other
APLtg 3 3A9 mice (not shown). (B) Three-
color FACS® analysis was performed on the
APLtg 3 3A9 mice described in Table III.
Representative dot plots of CD4 (PE) versus
CD8 (FITC) are shown. Compared with the
3A9 control in Fig. 7 A, all mice show a charac-
teristic loss of DP and CD4-SP thymocytes
consistent with negative selection. Thus, these
data directly demonstrate that all transgenes are
expressed, processed, and presented by thymic
APCs.1541 Williams et al.
Discussion
In this study, we have determined the effect of a broad
spectrum of APLs on the selection of an MHC class II–
restricted, antigen-specific transgenic T cell in vivo. We
find a strong correlation between the effect of the ligand on
thymocyte selection and the relative biological activity of
the ligand. Specifically, all ligands with measurable relative
activities in vitro produce some level of negative selection
in vivo. When combined with our previous observation
that the relative biological activity is kinetically related to
half-life of the TCR–ligand complex (47), the data demon-
strate that all ligands examined with a half-life .2 s in vitro
produce complete negative selection in vivo. Thus, these
results establish a kinetic threshold for the negative selec-
tion of an MHC class II–restricted TCR. Negatively se-
lecting ligands include both weak agonists and antagonists
of mature T cells. Our results also identify one ligand
(Q72) that appears to enhance the positive selection of spe-
cific thymocytes. Q72 has no effect on mature 3.L2 T cells,
and no binding can be detected in BIAcore™ experiments.
However, when expressed in the thymus of 3.L2tg mice,
this ligand results in increased numbers of CD4-SP thy-
mocytes with high levels of the 3.L2 clonotypic receptor.
E72, another ligand with no effect on mature 3.L2 T cells,
has no effect on 3.L2tg T cell development. Taken to-
gether, these results clearly illustrate an ordered progression
from negative selection to positive selection to no effect, as
the potency of the ligand is decreased. When combined
with the affinity measurements of ligand binding, they sug-
gest that there are kinetic thresholds for negative and posi-
tive selection which are related to the half-life of the
TCR–ligand complex. Specific interactions between TCR
and ligand of sufficient longevity will result in negative se-
lection, whereas weaker (shorter) interactions may be suffi-
cient for positive selection. The results also suggest that
positive selection involves specific interactions between
TCR and ligand, as only one of the two weak or null ligands
examined increased the percentage of specific T cells.
For the ligands used in this study, the correlation be-
tween the biological activity on mature T cells and the
half-life of the TCR–ligand complexes in vitro is compel-
ling. Accordingly, we have chosen to interpret the in vivo
selection data using a kinetic model of thymocyte selection,
as this model best fits all of the available data (47). Other
interpretations are possible, particularly when using nega-
tive selection as the sole parameter to be correlated with
the kinetic measurements. Specifically, on the basis of neg-
ative selection alone, one could use an occupancy model to
interpret the data. In this model, negative selection of
3.L2tg T cells would result for all ligands that bind the
TCR with an equilibrium binding affinity of 170 mM or
greater, the limit of detectable binding in our experiments.
Recent data from a single peptide/MHC class II com-
plex system suggest that a substantial increase in the con-
centration of a positively selecting ligand can result in neg-
ative selection (39). We have no direct information on how
the small differences in the level of expression of endog-
enous membrane proteins in this study might influence the
number of available peptide/MHC complexes derived from
these proteins. Data using an mAb to detect specific MHC/
peptide complexes on the cell surface have suggested that
only a fraction of the class II molecules on an APC may be
available for loading with a single epitope. These experi-
ments also suggested that there may be an upper limit to
the fraction of class II that can be loaded from endog-
enously expressed membrane proteins (64). The 3A9 T cell
hybridoma assays described above demonstrate that, for at
least this particular functional assessment, the consequences
of slight differences in expression are minimal. One inter-
pretation is that we have achieved maximal or near-maxi-
mal levels of the appropriate complexes using our approach
of continuously delivering the transgenic membrane pro-
tein to the class II antigen processing pathway in all APCs.
Furthermore, in a kinetic model, outcome is determined
primarily by the TCR dissociation rate, which does not de-
pend on ligand concentration. This important distinction
makes it unlikely that the three- to fivefold difference in
expression of the APL transgenes would have any effect on
negative selection, where the association between APL and
TCR–ligand half-life is strongest. Additionally, data from
our laboratory using an inducible system to control expres-
sion of N72(wt) support this conclusion (not shown).
Therefore, for example, the significant differences between
the effects of I72 and A72 on negative selection cannot be
explained by small differences in ligand concentration.
The relationship between TCR–ligand kinetics and pos-
itive selection remains speculative, as the half-lives of the
relevant complexes cannot be accurately measured with
current technology. Furthermore, practical considerations
in this study have limited our investigations to one level of
expression for each ligand; thus, the influence of ligand
density on positive selection remains to be determined. It is
possible, for example, that the A72 ligand expressed at
lower levels could give a result similar to that seen with
Q72, as predicted by an occupancy model of thymic selec-
tion. One way to integrate occupancy and kinetic models is
to postulate that signaling in both positive and negative se-
lection requires a certain number of complexes with an ap-
propriate half-life. Once the occupancy threshold is ex-
ceeded, the relevant kinetic parameter becomes the stability
of the TCR–ligand complex. Short-lived complexes could
result in contact caps with a different composition of sig-
naling molecules than complexes with longer half-lives (65,
66), thereby altering subsequent events in the signaling cas-
cade. Differential, ordered phosphorylation of the TCR z
chain has been observed in mature T cell signaling (24),
and it is not unreasonable to postulate a similar process in
developing thymocytes. Thus, positive and negative selec-
tion may involve distinct signaling pathways (67).
It is important to note that adding one specific ligand to
the pool of endogenous ligands is not a definitive test of
positive selection per se. On any particular background,
positive selection may already be maximized, so that the1542 APLs and T Cell Development
only additive effect that could be observed would be nega-
tive selection. We feel that, as indicated by the data pre-
sented here and elsewhere (53), this is not the case for 3.L2tg
T cells. Therefore, the observed transition from negative se-
lection to positive selection to no effect matches the pre-
dicted outcome as the potency of the ligand is decreased.
In summary, we have presented data examining the role
of APLs in thymic selection of 3.L2 T cells in vivo. Our
system individually adds one specific ligand at one fixed
concentration to MHC class II–positive cells in the thymus
and spleen. Under these conditions, we find that all ligands
with measurable effects on mature T cells produce at least
some level of negative selection. We also find that one par-
ticular null ligand, Q72, enhances the development of 3.L2tg
T cells. These observations lead us to conclude that there is
a direct correlation between the biological activity of the
APLs of 3.L2tg T cells and their effects on thymic selec-
tion. We have previously demonstrated that these biologi-
cal effects reflect the stability of the interaction between
3.L2tg T cells and each MHC/peptide complex (47). The
logical conclusion is that there are kinetic thresholds for
positive and negative selection related to the half-life of the
TCR–ligand complex.
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